-

Simulations Plus to Present at 16th Annual Needham Virtual Technology & Media Conference

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that chief executive officer Shawn O’Connor will present at the 16th Annual Needham Virtual Technology and Media Conference on Thursday, May 20, 2021, at 1:30 p.m. ET. In addition to his presentation, Mr. O’Connor will be joined by chief financial officer Will Frederick to host one-on-one meetings throughout the day.

This year’s conference will provide shareholders and investors the opportunity to see presentations from more than 350 public and private company management teams. For more information about the conference or to schedule a one-on-one meeting with Simulations Plus, please contact Hayden IR at slp@haydenir.com, or visit the Needham conference website.

About Simulations Plus, Inc.

Serving clients worldwide for 25 years, Simulations Plus, Inc., is a leading provider of modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions. With our subsidiaries, Cognigen, DILIsym Services, and Lixoft, we offer solutions which bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, chemical, consumer goods companies and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com. Follow us on Twitter | Read our Environmental, Social, and Governance (ESG) Report.

Contacts

Simulations Plus Investor Relations
Ms. Renee Bouche
(661) 723-7723
renee@simulations-plus.com

Hayden IR
Mr. Brian S. Siegel, IRC®, M.B.A.
(346) 396-8696
slp@haydenir.com

Simulations Plus, Inc.

NASDAQ:SLP

Release Summary
Simulations Plus CEO Shawn O'Connor will participate in the 16th Annual Needham Virtual Technology & Media Conference on Thursday, May 20, 2021.
Release Versions

Contacts

Simulations Plus Investor Relations
Ms. Renee Bouche
(661) 723-7723
renee@simulations-plus.com

Hayden IR
Mr. Brian S. Siegel, IRC®, M.B.A.
(346) 396-8696
slp@haydenir.com

Social Media Profiles
More News From Simulations Plus, Inc.

Simulations Plus Supports New FDA Roadmap for Reducing Animal Testing in Preclinical Safety Studies

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced its support of the U.S. Food and Drug Administration’s (FDA) recently announced roadmap for reducing animal testing through the use of new approach methodologies (NAMs). Simulations Plus has long provided the i...

Simulations Plus and Enabling Technologies Consortium Announce Strategic Collaboration to Advance GastroPlus® Enhancements

RESEARCH TRIANGLE, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it has entered a new funded collaboration with the Enabling Technologies Consortium (ETC). This partnership is aimed at advancing in vitro-in vivo correlation (IVIVC) approaches for oral drug delivery and expanding the function...

Simulations Plus Supported Development of Majority of FDA-Approved Drugs in 2024

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--SLP highlighted its impact on the pharma industry through support of the development of a majority of the drugs approved by the U.S. FDA in 2024....
Back to Newsroom
  1. There was an issue with the authorization server. Please contact support if the issue persists.